BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mannino DM. Biomarkers for chronic obstructive pulmonary disease diagnosis and progression: insights, disappointments and promise. Curr Opin Pulm Med 2019;25:144-9. [PMID: 30520743 DOI: 10.1097/MCP.0000000000000549] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Bamodu OA, Wu S, Feng P, Sun W, Lin C, Chuang H, Ho S, Chen K, Chen T, Tseng C, Liu W, Lee K. lnc-IL7R Expression Reflects Physiological Pulmonary Function and Its Aberration Is a Putative Indicator of COPD. Biomedicines 2022;10:786. [DOI: 10.3390/biomedicines10040786] [Reference Citation Analysis]
2 Li S, Zhao S, Wu Z, Wang F, Li W. Alteration of immune profiles is associated with pulmonary function and symptoms in patients with chronic obstructive pulmonary disease. Mol Med Rep 2021;24:742. [PMID: 34435653 DOI: 10.3892/mmr.2021.12382] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Burkes RM, Panos RJ. Ultra Long-Acting β-Agonists in Chronic Obstructive Pulmonary Disease. J Exp Pharmacol 2020;12:589-602. [PMID: 33364854 DOI: 10.2147/JEP.S259328] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Cazzola M, Puxeddu E, Ora J, Rogliani P. Evolving Concepts in Chronic Obstructive Pulmonary Disease Blood-Based Biomarkers. Mol Diagn Ther 2019;23:603-14. [PMID: 31363933 DOI: 10.1007/s40291-019-00413-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
5 Rong B, Fu T, Gao W, Li M, Rong C, Liu W, Liu H. Reduced Serum Concentration of CC16 Is Associated with Severity of Chronic Obstructive Pulmonary Disease and Contributes to the Diagnosis and Assessment of the Disease. Int J Chron Obstruct Pulmon Dis 2020;15:461-70. [PMID: 32184583 DOI: 10.2147/COPD.S230323] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
6 Burkes RM, Ceppe AS, Couper DJ, Comellas AP, Wells JM, Peters SP, Criner GJ, Kanner RE, Paine R 3rd, Christenson SA, Cooper CB, Barjaktarevic IZ, Krishnan JA, Labaki WW, Han MK, Curtis JL, Hansel NN, Wise RA, Drummond MB; SPIROMICS collaborators. Plasma Cathelicidin is Independently Associated with Reduced Lung Function in COPD: Analysis of the Subpopulations and Intermediate Outcome Measures in COPD Study Cohort. Chronic Obstr Pulm Dis 2020;7:370-81. [PMID: 33108110 DOI: 10.15326/jcopdf.7.4.2020.0142] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Wells JM, Xing D, Viera L, Burkes RM, Wu Y, Bhatt SP, Dransfield MT, Couper DJ, O'Neal W, Hoffman EA, Gaggar A, Barjaktarevic I, Curtis JL, Labaki WW, Han MLK, Freeman CM, Putcha N, Schlange T, Blalock JE; SPIROMICS Investigators,. The matrikine acetyl-proline-glycine-proline and clinical features of COPD: findings from SPIROMICS. Respir Res 2019;20:254. [PMID: 31718676 DOI: 10.1186/s12931-019-1230-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
8 Young KA, Regan EA, Han MK, Lutz SM, Ragland M, Castaldi PJ, Washko GR, Cho MH, Strand M, Curran-Everett D, Beaty TH, Bowler RP, Wan ES, Lynch DA, Make BJ, Silverman EK, Crapo JD, Hokanson JE, Kinney GL; COPDGene® Investigators. Subtypes of COPD Have Unique Distributions and Differential Risk of Mortality. Chronic Obstr Pulm Dis 2019;6:400-13. [PMID: 31710795 DOI: 10.15326/jcopdf.6.5.2019.0150] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]